Drug Profile
Prostate cancer vaccine - CellGenix
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CellGenix Technologie Transfer
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in Germany
- 10 Aug 2007 Preclinical development is ongoing
- 06 Dec 2006 Preclinical development is still ongoing